Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zenobia Therapeutics, a provider of fragment-based lead discovery for diseases of the central nervous system, has successfully completed the first phase of its services agreement with Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec.
Subscribe to our email newsletter
As part of the agreement, Syntonix gains access to Zenobia’s technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia has completed three unique protein structures during the first five months of the agreement. The agreement includes research funding and milestone payments.
Zenobia has access to high-energy synchrotron sources for data collection through an agreement with Shamrock Biostructures, located near the Advanced Photon Source in Chicago, Illinois.
Vicki Nienaber, president and chief scientific officer of Zenobia, said: “Syntonix challenged us with a difficult program, and through close collaboration between our scientists, we are pleased to deliver results.”